课题基金 / 基金详情

A novel paradigm for effective and safer treatment of schizophrenia: biased (ant)agonists with a characterized polypharmacological profile

A novel paradigm for effective and safer treatment of schizophrenia: biased (ant)agonists with a characterized polypharmacological profile
有效且更安全地治疗精神分裂症的新范例：具有多药理特征的偏向（蚂蚁）激动剂
批准号：
387321
负责人：
Bouvier Michel
金额：
$7.29万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-06-01 至 2021-06-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=387321&lang=en
关键词：
Antipsychotics Biased Signalling G Protein-Coupled Receptors Monoamine Receptors Resonance Energy Transfer (Bret-Fret) Schizophrenia Serotonin Receptor Signalling Pathways

项目摘要

项目成果

Bouvier Michel的其他基金

相似基金

相关文献

中文摘要
翻译
精神分裂症(SZ)是一种严重的疾病，影响1-2%的人口。目前的治疗与副作用有关，如运动协调问题、思维减慢的感觉、大脑中异常的电活动、心脏节律改变
英文摘要
Schizophrenia (SZ) is a severe disease affecting 1-2% of the population. Current treatment is associated to side effects such as motor coordination problems, a feeling of the mind slowing down, abnormal electrical activity in the brain, altered heart rhyt
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular mechanisms and structural determinants of pharmacological chaperone action; therapeutic potential for the treatment of early onset severe obesity
Mechanisms and consequences of spatially controlled G protein-coupled receptor signaling
G protein functional selectivity in metabolic disorders
Assembly, trafficking and regulation of G protein-coupled receptor signaling complexes
  • 批准号：
    344989
  • 项目类别：
    Operating Grants
  • 资助金额：
    $88.83万
  • 财政年份：
    2016
  • 负责人：
    Bouvier Michel
  • 依托单位：
    Universit de Montral
海外基金